People with HIV experience less bone loss if they switch to a NRTI-sparing second-line regimen containing raltegravir, researchers reported last week at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention this week in Kuala Lumpur.
http://www.hivandhepatitis.com/hiv-related-conditions/hiv-bone-loss-osteoporosis/4193-ias-2013-studies-look-at-bone-changes-during-second-line-therapy-fractures-and-hiv-and-hcv-related-bone-loss
http://www.hivandhepatitis.com/hiv-related-conditions/hiv-bone-loss-osteoporosis/4193-ias-2013-studies-look-at-bone-changes-during-second-line-therapy-fractures-and-hiv-and-hcv-related-bone-loss
No comments:
Post a Comment